- 
                                    
                                        
                                            Anti IPD
                                        
                                            
                                                
                                                    
                                                    
                                                        Pneumococcal 13 
 Project in collaboration with Partners
 
 
 
 
 
                                - 
                                    
                                        
                                            Anti IMD
                                        
                                            
                                                
                                                    
                                                    
                                                        Meningococcal Group ACWY 
 Project in collaboration with Partners
 
 
                                                    
                                                    
                                                        Meningococcal Group B L8 Endotoxoid 
                                                                 (Concept for Safety Phase I)
                                                            
                                                     
 
                                                    
                                                    
                                                        Meningococcal Group B L7 Endotoxoid 
 (Nanostructured VS)
 
 
                                                    
                                                    
                                                        Meningococcal Pentavalent (A,B,C,W,Y)
                                                     
 
 
 
 
                                - 
                                    
                                        
                                            Multidrug Resistance
                                        
                                            
                                                
                                                
                                                    
                                                    
                                                        - Escherichia Coli 
 - Salmonella Typhi
 
 
                                                    
                                                    
                                                        - Klebsiella pneumoniae
 - Pseudomonas aeruginosa
 -
                                                        Acinetobacter baumannii
 
 
 
 
 
                                - 
                                    
                                         
                                            Nanostructured Vector System for Viral subunit  vaccines
                                        
                                        
                                            
                                                
                                                
                                                    - COV-2 
 - RSV
 - Influenza
 
 
 
 
 
 
                     
                 
             
         
    
    
    
    
        BiosYnth s.r.l. - P.IVA 00736000522 - Capitale Sociale: € 520.000 I.V.
    
    
         Developed by
         